Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $16.59. Which is the better fit depends on your goals.
| ACAD | PDBC | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $18.91 |
52-Week Low | $20.06 | $12.90 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PDBC trades at $16.32, up 2.84% today, with a bullish technical signal despite mixed moving averages and oscillators. The ETF has delivered strong returns, including 37% gains since March 2024, outperforming the S&P 500, though recent commodity momentum has softened. Its structure avoids K-1 tax forms, attracting $4.6 billion in assets as an inflation hedge.
Outlook remains cautiously optimistic given commodity price volatility and geopolitical risks. Opportunities include continued inflation hedging demand, but risks involve oil price declines and unpredictable annual distributions. Recent downgrade to hold reflects near-term caution amid supply disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
